At-Birth Immunisation Against Hepatitis B Using a Novel Pre- Filled Immunisation Device Stored Outside the Cold Chain

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

At-Birth Immunisation Against Hepatitis B Using a Novel Pre- Filled Immunisation Device Stored Outside the Cold Chain

Vaccine Online (10/14/99) Vol. 18, Nos. 5 and 6, P. 498
Otto, Bradley F.; Suarnawa, I. Made; Stewart, Tony; et al.

Researchers studied the immunogenicity of hepatitis B virus (HBV) vaccine in the UniJect injection device in a cohort of infants in Bali. The pre-filled, non-reusable device can be stored at tropical temperatures for up to one month. The infants received their first dose of HBV vaccine either from UniJect stored outside of the cold chain; UniJect stored in the cold chain; or with a standard syringe, needle, and multidose vial stored in the cold chain. Additional doses were administered by standard means. Based on blood samples taken four to six weeks after the third dose, there were no significant differences in seroconversion rates or geometric mean titres of HBV surface antibody in any of the groups.

991022
AD991791

Copyright © 1999 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.